New Chemotherapeutic Agents

Evaluation of Chemotherapeutic Agents

This fourth, thoroughly revised, edition of Calmette's well-known manual aims to bring together the maximum of information which will be of value to the bacteriologist in his daily work. It is based largely on the techniques utilized at the Pasteur Institute in Paris. The topics included differ from those found in similar manuals in this country which are usually texts of laboratory diagnosis a...

Enzymes as Chemotherapeutic Agents

New chemotherapeutic agents for non-small cell lung cancer.

The identification of new chemotherapeutic agents for the treatment of non-small cell lung cancer should proceed in a structured, logical fashion. Agents should be evaluated on the basis of multiple objective and subjective end points. A 15% or greater major objective response rate, demonstrated in multiple single-agent phase II trials, is considered the lower limit for an agent to be deemed cl...

Tubulin/microtubules: still a promising target for new chemotherapeutic agents.

Most investigators would agree that the ideal chemotherapeutic agent should be 1) directed at a validated target; 2) potent, preferably active at nanomolar or subnanomolar concentrations; 3) schedule independent, even active in noncycling cells; 4) active against drug-resistant cells; and 5) less toxic or ideally not toxic to normal cells. In this issue of the Journal, Leoni et al. (1) suggest ...

Medication Errors in Administration of Chemotherapeutic Agents: an Observational Study

Chemotherapy medication errors may lead to potentially harmful consequences while most of them could be preventable. This study aims to determine the incidence and type of drug handling and administration errors among the nurses and to identify possible contributing factors. Setting of the study was a teaching hospital affiliated to Shahid Beheshti University of Medic...